Paritaprevir

Summary

Paritaprevir (CHEMBL3391662) is an approved small molecule; indicated across 3 conditions including chronic hepatitis c virus infection and hepatitis c virus infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 68
• Chemistry: 765.9 Da · C40H43N7O7S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3391662
Name	Paritaprevir
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	45110509
Molecular formula	C40H43N7O7S
Molecular weight	765.9
InChIKey	UAUIUKWPKRJZJV-QPLHLKROSA-N

SMILES: CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8

IUPAC name: (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide

Also known as: ABT-450, Paritaprevir, Paritaprevir component of technivie, Paritaprevir component of viekirax, Veruprevir, Veruprevir anhydrous, PARITAPREVIR, paritaprevir, Parataprevir, ParitaprevirÊ, ParitaprevirÂ, VERUPREVIR

Parent form; salt/anhydrous children: CHEMBL3781660

Patent coverage: 522 distinct patent families (1,197 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,089 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
chronic hepatitis C virus infection	4	MONDO:0005354	EFO:0004220
hepatitis C virus infection	4	MONDO:0005231	EFO:0003047

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hepatitis B virus infection	2	MONDO:0005344	EFO:0004197

Clinical trials

Total trials: 68.

Phase distribution

Phase	Trials
PHASE3	30
PHASE2	14
Not specified	9
PHASE4	6
PHASE1	6
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02460133	PHASE4	ACTIVE_NOT_RECRUITING	Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment
NCT02786537	PHASE4	COMPLETED	Study of Oral Treatments for Hepatitis C
NCT02992457	PHASE4	COMPLETED	Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection
NCT03296930	PHASE4	UNKNOWN	Effect Of DAAs For Treatment Of HCV On Normal Kidney
NCT03499639	PHASE4	COMPLETED	Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease
NCT03710252	PHASE4	COMPLETED	A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study
NCT01674725	PHASE3	COMPLETED	A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
NCT01704755	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
NCT01715415	PHASE3	COMPLETED	A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
NCT01716585	PHASE3	COMPLETED	A Study to Evaluate Chronic Hepatitis C Infection
NCT01767116	PHASE3	COMPLETED	A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
NCT01773070	PHASE3	COMPLETED	A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
NCT01833533	PHASE3	COMPLETED	A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
NCT01854528	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults
NCT01854697	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
NCT01939197	PHASE2/PHASE3	COMPLETED	A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
NCT02023099	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
NCT02023112	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
NCT02167945	PHASE3	COMPLETED	A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
NCT02207088	PHASE3	COMPLETED	Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
NCT02216422	PHASE3	COMPLETED	A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
NCT02219477	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
NCT02219490	PHASE3	COMPLETED	A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
NCT02219503	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
NCT02265237	PHASE3	COMPLETED	A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
NCT02399345	PHASE3	COMPLETED	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults
NCT02442271	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil
NCT02442284	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
NCT02476617	PHASE3	COMPLETED	Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
NCT02486406	PHASE2/PHASE3	COMPLETED	A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
NCT02487199	PHASE3	COMPLETED	Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease
NCT02504099	PHASE3	TERMINATED	A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma
NCT02517515	PHASE3	COMPLETED	ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
NCT02517528	PHASE3	COMPLETED	ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
NCT02555943	PHASE2/PHASE3	COMPLETED	DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
NCT02582632	PHASE3	COMPLETED	A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
NCT02609659	PHASE3	COMPLETED	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
NCT02634008	PHASE3	COMPLETED	Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
NCT02806362	PHASE3	WITHDRAWN	Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
NCT01074008	PHASE2	COMPLETED	A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
NCT01221298	PHASE2	COMPLETED	A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
NCT01306617	PHASE2	COMPLETED	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
NCT01458535	PHASE2	COMPLETED	A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
NCT01464827	PHASE2	COMPLETED	ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients
NCT01563536	PHASE2	COMPLETED	Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
NCT01672983	PHASE2	COMPLETED	A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection
NCT01782495	PHASE2	COMPLETED	A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
NCT01911845	PHASE2	COMPLETED	An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine
NCT01995071	PHASE2	COMPLETED	A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
NCT02068222	PHASE2	COMPLETED	A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection
NCT02194998	PHASE2	TERMINATED	Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
NCT02356562	PHASE2	COMPLETED	A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
NCT02493855	PHASE2	COMPLETED	Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
NCT00850044	PHASE1	COMPLETED	Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1
NCT00909311	PHASE1	COMPLETED	Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
NCT00931281	PHASE1	COMPLETED	Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
NCT01091649	PHASE1	COMPLETED	Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450
NCT02052362	PHASE1	COMPLETED	Bioavailability of ABT-450 and ABT-267 With Ritonavir
NCT02534870	PHASE1	COMPLETED	Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
NCT02581163	Not specified	COMPLETED	Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
NCT02581189	Not specified	COMPLETED	Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
NCT02582671	Not specified	COMPLETED	The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
NCT02725866	Not specified	COMPLETED	Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
NCT02758509	Not specified	COMPLETED	Impact of Antiviral Therapy on Gastroesophageal Varices.
NCT02803138	Not specified	COMPLETED	Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
NCT03122132	Not specified	COMPLETED	Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks
NCT03549832	Not specified	COMPLETED	Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
NCT04047680	Not specified	COMPLETED	eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).